HPR vs Retinol: Grade Selection, Dosage and Formulation Guide

HydroxypinacoloneRetinoate

Formulation guide · ZLEY Group
Source check: 30 October 2026. Published supplier specifications are identified below. Proposed trials are development recommendations. No named scientist review or new clinical evaluation is claimed.

Hydroxypinacolone Retinoate, commonly called HPR, is a cosmetic retinoid ingredient that requires grade-specific formulation work. Selecting a powder or diluted carrier system changes the weighing calculation, solvent contribution and manufacturing route. A useful comparison with retinol should help a formulator make those choices, while keeping ingredient identity, finished-product performance and marketing claims separate.

This guide focuses on ZLEY®HPR powder and the questions to resolve before comparing it with ZLEY®HPR-10 or a retinol delivery system. Use the current controlled supplier documents and a lot-specific COA to finalize a commercial specification.

Published ZLEY HPR powder specifications

Grade-specific information from the published TDS and SDS
Parameter Published information
INCI Hydroxypinacolone Retinoate
CAS 893412-73-2
Appearance Yellow crystalline powder
Purity NLT 99.0% by HPLC
Suggested use level 0.01–0.3% for the supplied powder, according to the TDS
System selection TDS describes oil-based and selected emulsion systems; does not recommend pure-water systems or dilute emulsions.
pH / addition temperature No universal finished-formula pH range or maximum addition temperature specified in the linked powder TDS.
Storage / packaging Cool, dry storage; two years; 1 kg aluminum film bag with polyethylene lining in the TDS.

The powder TDS refers to dilute emulsions with viscosity below “1500” without specifying a unit or measurement method. Obtain clarification before treating that number as an acceptance criterion. Viscosity depends on the instrument, temperature and shear conditions, so attaching a familiar unit to an incomplete statement would make the specification appear more precise than the source supports.

HPR versus retinol: compare supplied materials and evidence

HPR and retinol are different molecules within the broader retinoid family. Neither a shared category nor similar product positioning establishes an equivalent dose. Raw retinol, encapsulated retinol, high-purity HPR and an HPR carrier blend bring different compositions into a formula. Compare identity, active fraction, carrier requirements and the evidence available for the actual material under consideration.

Questions that make a retinoid comparison useful
Decision HPR powder Diluted HPR or retinol delivery system
Weighing Small additions may require a validated concentrate and suitable balance. Calculate the supplied-blend amount from the verified active fraction.
Carrier contribution Choose and validate the solvent route. Include the existing carrier in solvent, emollient and compatibility calculations.
Process Confirm dissolution, temperature and addition sequence. Confirm whether the system is dissolved, dispersed or encapsulated and follow its own instructions.
Performance claim Evaluate the finished formula at its selected active level. Evaluate the finished formula; a delivery-system description is not a tolerance guarantee.

A published study of a serum combining retinol, HPR, peptides and silybin reports mechanistic and clinical findings for that multi-active formulation. It cannot isolate the contribution of HPR, demonstrate that HPR alone outperforms retinol or validate a ZLEY grade. Use it as formulation context while requesting the underlying protocols and material-specific evidence needed for your own claim.

Claims such as “non-irritating,” “suitable for all sensitive skin” or “equivalent to a higher retinol dose” require appropriate support. A purchasing decision should not depend on those phrases without concentrations, vehicle details, comparator information and test methods. Tolerance depends on the full formula and use conditions, and an ingredient substitution creates a new development question even when the intended consumer benefit is similar.

Calculate active HPR before selecting a use level

For a blend with a verified mass fraction, nominal active percentage in the finished product equals blend percentage multiplied by the active fraction. For example, if a hypothetical blend contains 10% HPR by mass, a 1% blend addition contributes 0.10% nominal HPR. This arithmetic example is not a recommended use level or confirmation of any commercial grade’s assay.

Do not substitute an HPLC area-purity value directly for a mass-content assay unless the supplier confirms that this interpretation is appropriate. HPLC purity describes the stated analytical measurement; it may not by itself account for water, residual solvents or the assay basis needed for exact dosing. Agree on whether calculations use nominal specification, an actual content assay or another justified basis.

For small laboratory batches, assess the practical weighing error. A tiny powder addition near the balance’s reliable operating limit can create significant concentration variation. A validated stock solution may improve handling, but its composition, expiry, light protection and homogeneity need control. Record the stock preparation as part of the batch procedure and account for its carrier in the final formula.

Solubility, pH and manufacturing sequence

The published SDS identifies several compatible solvents, including selected glycols, ethoxydiglycol and dimethyl isosorbide. That list describes raw-material solubility information, not unrestricted permission to use every solvent in every cosmetic market. Select a carrier suitable for your intended product and destination, then check its effect on sensory properties, packaging, preservation and tolerance.

The powder TDS does not recommend direct use in pure-water systems. If the brief calls for a lightweight aqueous serum, evaluate an appropriate delivery architecture with technical support rather than forcing the powder into water and calling the result soluble. An emulsion, solvent-supported system and dispersion have different behavior. Initial uniformity does not establish long-term physical stability or uniform dosing during use.

Build the process around a documented sequence: prepare the base, prepare and inspect any concentrate, introduce the active using the validated conditions, then mix to a defined endpoint. Check the complete formula after equilibration and cooling. Record actual product temperature and exposure time, because a vessel set-point alone does not describe what the active experiences.

The melting-point entry in a powder specification is not a recommended addition temperature. Likewise, a pH range quoted for retinol or another commercial HPR blend does not establish the correct range for this grade. Ask for a grade-specific process recommendation and screen the proposed formula across a justified operating window. Where pH is meaningful, use a repeatable method and track changes during storage.

Compatibility, antioxidant support and packaging

The supplier TDS recommends considering antioxidants, chelating agents and light-protective, airtight packaging. Translate those suggestions into comparisons with measurable endpoints. Choose support ingredients for the actual formula instead of treating them as automatic stabilizers. Their own solubility, pH requirements, impurities and sensory effects can influence the outcome.

When combining HPR with niacinamide, peptides, soothing ingredients or antioxidants, begin with a stable base and introduce complexity in controlled steps. Compare base-only, retinoid-only and combination samples where useful. This helps distinguish active loss from emulsion instability or changes caused by another component. Compatibility is a property of a defined system, concentration and process, rather than a blanket yes-or-no relationship between two ingredient names.

Suggested HPR development matrix
Variable What to compare What to record
Carrier and process Selected solvent packages and realistic addition conditions Homogeneity, crystals, viscosity, active recovery and batch consistency
Supporting actives Retinoid-only reference and complete combination Assay, pH where applicable, appearance and physical stability
Packaging Candidate commercial pack and suitable reference Active retention, leakage, dispensing, compatibility and in-use changes
Storage Project-specific accelerated and real-time conditions Defined acceptance criteria and trends rather than a single pass/fail observation

Use an analytical method suitable for the formulation matrix. A color observation alone cannot establish the amount of active remaining. If recovery changes unexpectedly, examine sample extraction and assay suitability as well as chemical degradation. Retain batch records and reference samples so that a supplier or laboratory can investigate a discrepancy without relying on memory.

For packaging, consider oxygen access during repeated dispensing, light transmission, headspace and contact materials. An airless description does not replace a compatibility trial. Include the intended fill process and foreseeable transport conditions. A pack that performs well with the base may behave differently after adding the solvent package or active concentrate.

Scale-up and change control

Before production, repeat the selected formula in independent batches and define the process limits that matter. Mixing intensity, addition rate, hold time and temperature history can differ substantially between beaker and vessel. Document the critical observations and establish a sampling plan that can reveal nonuniformity. Preserve the approved raw-material grade and carrier composition in the manufacturing specification.

Reassess meaningful substitutions. A change in HPR format, solvent supplier, emulsifier, antioxidant or packaging can affect both the concentration calculation and stability. Supplier change-control procedures and a clear internal approval record reduce the chance that an apparently equivalent replacement reaches production without the necessary evaluation.

What to include in an HPR sample request

Send the intended format, target active level, batch size, solvent restrictions, temperature limits, destination market and required documents. Ask for the current TDS, SDS, batch COA, assay basis, impurity controls, carrier composition where relevant, storage instructions and any available formulation or study protocols. Confirm MOQ, packaging, lead time and availability through the quotation.

For a powder-versus-blend decision, ask the technical team to explain which process steps change and how the supplied active content is verified. If requesting efficacy data, specify the claim and population you intend to assess. A documented, testable development brief is more useful than a request for a universally “best” retinoid.

Request ZLEY HPR samples / technical documents

Formulation FAQ

What is the recommended use level for ZLEY HPR?

The published TDS suggests 0.01–0.3% for ZLEY HPR powder with NLT 99.0% HPLC purity. A diluted HPR blend requires its own active-content calculation and supplier instructions.

Can ZLEY HPR powder be used in a pure-water serum?

The published TDS does not recommend this grade for pure-water systems or dilute emulsions. Select an appropriate carrier and formulation architecture with technical support, then validate compatibility and stability.

What pH and processing temperature should I use for HPR?

The linked powder TDS does not specify a universal finished-formula pH range or maximum addition temperature. Request grade-specific process guidance rather than inferring a limit from the melting point or another retinoid.

Sources and scope

Technical review, sources and testing

Content role
Formulation guide
Technical review owner
ZLEY Group
Review status
Public supplier sources cross-checked; proposed bench workflow requires formulation validation. No named scientist sign-off is claimed.
Source check date

Sources and controlled documents

Testing and evidence note

Published supplier document facts are identified in the guide. Bench workflows and calculations are proposed evaluation tools, not completed test results, clinical validation or target-market regulatory clearance. Obtain current controlled documents and validate the finished formulation.